Cardiology

Trials, guidelines and practice across cardiovascular medicine.

SGLT2 Inhibitors, GLP-1RAs and MRAs May Reshape Heart Failure Burden

JACC abstract examines how SGLT2 inhibitors, GLP-1RAs, and nonsteroidal MRAs could alter the anticipated burden of heart failure.

Pelacarsen lowered lipoprotein(a) by 78% in Lp(a) HORIZON, yet major cardiovascular events did not improve in more than…

Ziltivekimab cut inflammatory markers in ZEUS but did not reduce major cardiovascular events in very high-risk adults with…

The 2025 AHA statistical update compiles US and global data on cardiovascular risk, outcomes, health equity, and care…

A meta-analysis of 10 studies found early invasive NSTEMI care lowered mortality and heart-failure rehospitalization, but not recurrent…

A narrative review links Qur’anic heart concepts with neurocardiology, vagal signaling, cardioception, and social synchrony in modern cardiac…

In FAVOR III China, QFR-guided PCI was linked to fewer 3-year major adverse cardiac events than angiography guidance…

A 2026 review maps cardiovascular ageing hallmarks, pathways, and FDA-approved and experimental targets to reduce residual risk in…

A clinical abstract compares super-low-dose edoxaban 15 mg with reduced-dose 30 mg in high-bleeding-risk patients, raising dosing and…

A PLOS One protocol outlines a scoping review of cardiovascular risk prediction models for people living with HIV…

Cardiology

Trials, guidelines and practice across cardiovascular medicine.

In Brief The 5-minute rounds